



27 Birchwood
Avenue
London
N10 3BE

T +44 (0) 208 365 2185
m +44 (0) 7818012891
info@phmrconsulting.com
www.phmrconsulting.com

Directors

Mark Ratcliffe
BSc MSc PhD
Peter Hudson
BSc MSc

Alzheimer's Disease

Economic/ health outcome publication alerts added in
February 2008

Searches found 91 articles that met criteria: 10 are commercially significant of
which 4 are business and scientific critical and are reviewed

Papers reviewed this month:

Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for Agitation/Aggression and Psychosis in Moderately Severe to Severe Alzheimer's Disease: A Pooled Analysis of 3 Studies. *J Clin Psychiatry*. 2008 Feb 20;e1-e8 [Epub ahead of print]

Martin R, Griffith HR, Belue K, Harrell L, Zamrini E, Anderson B, Bartolucci A, Marson D. Declining Financial Capacity in Patients With Mild Alzheimer Disease: A One-Year Longitudinal Study. *Am J Geriatr Psychiatry*. 2008 Mar;16(3):209-219. Epub 2008 Feb 8.

Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS; Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) investigators. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. *Arch Gen Psychiatry*. 2007 Nov;64(11):1259-68.

Getsios D, Migliaccio-Walle K, Caro JJ. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? *Pharmacoeconomics*. 2007;25(12):997-1006.

phmr consulting ltd.
Registered in England
Number 6551482
Registered office
Melville House
8-12 Woodhouse
Road
London N12 ORG